Charles Schwab Investment Management Inc Cassava Sciences Inc Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Cassava Sciences Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 265,290 shares of SAVA stock, worth $615,472. This represents 0.0% of its overall portfolio holdings.
Number of Shares
265,290
Previous 361,253
26.56%
Holding current value
$615,472
Previous $541,000
11.28%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding SAVA
# of Institutions
131Shares Held
14.2MCall Options Held
963KPut Options Held
866K-
Black Rock Inc. New York, NY3.22MShares$7.47 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$5.03 Million0.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny984KShares$2.28 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY790KShares$1.83 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY613KShares$1.42 Million0.0% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $93M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...